Unfortunately, its toxicity, the IL-2-driven stimulation of regulatory T cells (Tregs) and its limited efficacy have restricted the clinical use of this cytokine in tumor immunotherapies, and efforts have been made to improve its efficacy by combining it with other anti-cancer regimens and therapies [37]. The gene discussed is IL2; the disease is neoplasm.